I was interested to read in the ‘Our Blood’ supplement in today’s issue of The Guardian newspaper that this week is Lymphatic Cancer Awareness Week. The purpose of the week, which coincides with World Lymphoma Awareness Day on 15 September, is to raise awareness of the condition as well as promote research into new therapies. The article in the supplement quotes Dr Graham Collins, a consultant haematologist, who says that “promoting research into new treatments is absolutely vital. There are many exciting drugs being studied that can target the underlying biology of the lymphoma and be tailored to increasingly specific patient groups.”
The supplement also focussed on chronic myeloid leukaemia, which is diagnosed in about 600 people each year in the UK. With regards to new therapies for CML, Professor O’Brien, who is chief investigator of the SPIRIT 3 study that aims to compare the efficacy of new drug treatments, was quoted as saying “The evidence so far seems to indicate that, while they do not provide any significant improvement compared with existing treatments, in terms of survival, they could potentially improve our ability to stop treatment in the long term and cure the condition.”
The Our Blood supplement also featured a cameo appearance from our very own World Orphan Drug Congress Europe 2013!
How important do you think raising patient awareness is in the battle against lymphatic cancers and rare blood disorders?
The World Orphan Drug Congress Europe brings together pioneers from the orphan drug community, including key opinion leaders from the payer, HTA, public health and patient advocacy bodies. Download the brochure for the World Orphan Drug Congress Europe 2013, 14-15 November 2013, Geneva.